Semaglutide is a insulin-like peptide-1 receptor agonist (GLP-1 RA) developed by the Danish pharmaceutical company Novo Nordisk for the treatment of type 2 diabetes
Despite the availability of ongoing advances in diabetes research and development, this chronic medical condition is often not diagnosed promptly and treated appropriately, thus leading to increased rates of death or long-term disability
Retrieved October 15, 2023
Keep medications in their original pharmacy-labeled containers whenever possible
They can help you safely transition based on your goals and how your body has responded
How to switch from Mounjaro to Wegovy Since Mounjaro and Wegovy act in very similar ways, with similar ingredients and half-lives, switching between them is considered safe and effective, as long as its done under the supervision of a medical professional